A double-blind, randomized, placebo-controlled study to assess the efficacy of ketoconazole for reducing the risk of ovarian hyperstimulation syndrome

Fertility and Sterility

Volumn 80, Issue 5, 2003, Pages 1151-1155

  Parsanezhad, Mohammad Ebrahim ^a,b   Alborzi, Saeed ^b   Pakniat, Mahnaz ^b   Schmidt, Ernst Heinrich ^c  

^a Shiraz Univ of Medical Sciences ^*  (Iran)

^b SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c UNIVERSITY OF GÖTTINGEN   (Germany)

Author keywords

Gonadotropins; Hyperstimulation; Ketoconazole; Polycystic ovary

Indexed keywords

HUMAN MENOPAUSAL GONADOTROPIN; KETOCONAZOLE; PLACEBO;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; ESTROGEN BLOOD LEVEL; EVALUATION; FEMALE; HUMAN; INFERTILITY; OVARY FOLLICLE DEVELOPMENT; OVARY HYPERSTIMULATION; OVARY POLYCYSTIC DISEASE; OVULATION INDUCTION; PREGNANCY RATE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK; STEROIDOGENESIS;

EID: 0242577384     PISSN: 00150282     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0015-0282(03)01177-4     Document Type: Article

References (23)

1. Schenker J.G., Ezra Y. Complications of assisted reproductive techniques. Fertil Steril. 61:1994;411-422.
2. Aboulghar M.A., Mansour R.T., Serour G.I., Elhelw B.A., Shaarawy M. Elevated concentrations of angiogenin in serum and ascitic fluid from patients with severe ovarian hyperstimulation syndrome. Hum Reprod. 13:1998;2068-2071.
3. Pellicer A., Albert C., Mercader A., Musoles F., Remohi J., Simon C. The pathogenesis of ovarian hyperstimulation syndrome in vivo studies investigating the role of interleukin-1β, interleukin-6, and vascular endothelial growth factor . Fertil Steril. 71:1999;482-489.
4. Neulen J, Yan Z, Raczek S, Wiendel K, Keck C, Weich HA, et al. Human chorionic gonadotropin dependent expression of vascular endothelial growth factor/vascular permeability factor in human granulosa cells: importance in ovarian hyperstimulation syndrome. J Clin Endocrinol Metab;80:1967-71.
5. Yan Z., Weich H.A., Bernart W., Breckwoldt M., Neulen J. Vascular endothelial growth factor (VEGF) messenger ribonucleic acid (mRNA) expression in luteinized human granulose cells in vitro. J Clin Endocrinol Metab. 77:1993;1723-1725.
6. McLure N., Healy D.L., Rogers P.A., Sullivan J., Beaton L., Haning R.V., et al. Vascular endothelial growth factor as capillary permeability agent in ovarian hyperstimulation syndrome. Lancet. 344:1994;235-236.
7. Shweieki D., Itin A., Neufeld G., Gitay-Goren H., Keshet E. Patterns of expression of vascular endothelial growth factor (VEGF) and VEGF receptors in mice suggest a role in hormonally regulated angiogenesis. J Clin Invest. 91:1993;2235-2243.
8. Sher G., Salem R., Feinman M., Dodge S., Zouves C., Knutzen V. Elimination the risk of life-endangering complications following overstimulation with menotropin fertility agents; a report on women undergoing in vitro fertilization and embryo transfer. Obstet Gynecol. 81:1993;1009-1011.
9. Asch R.H., Li H.P., Balmaceda J.P., Weckstein L.N., Stone S.C. Severe ovarian hyperstimulation syndrome in assisted reproductive technology; definition of high risk groups. Hum Reprod. 6:1991;1395-1399.
10. Amso N., Ahuja K., Morris N., Shaw R.W. The management of predicted ovarian hyperstimulation involving gonadotropin releasing hormone analog with elective cryopreservation of all pre-embryos. Fertil Steril. 53:1990;1087-1090.
11. Amit A., Yaron Y., Yovel I., Peyser M.R., David M.P., Botchan A., et al. Repeated aspiration of ovarian follicles and early corpus luteum cysts in an in-vitro fertilization program reduced the risk of hyperstimulation syndrome in high responders. Hum Reprod. 8:1993;1184-1186.
12. Asch R.H., Ivery G., Goldsman M., Fredrick J.L., Stone S.C., Balmaceda J.P. The use of intravenous albumin in patients at high risk for severe ovarian hyperstimulation syndrome. Hum Reprod. 8:1993;1015-1020.
13. Ron E.R. Complications of ovulation induction. Baillieres Clin Obstet Gynecol. 7:1993;435-453.
14. Aboulghar M.A., Mansour R.T., Serour G.I., Amin Y.M. Ultrasonically guided vaginal aspiration of ascites in the treatment of ovarian hyperstimulation syndrome. Fertil Steril. 53:1990;933-935.
15. Sonino N. The use of ketoconazole as an inhibitor of steroid production. N Engl J Med. 317:1987;812-818.
16. Pepper G., Brenner S.H., Gabrilove J.L. Ketoconazole use in the treatment of ovarian hyperandrogenism. Fertil Steril. 54:1990;438-444.
17. Isik A.Z., Gokmen O., Zeyneloglu H.B., Senoz S., Zorlu C.G. Low dose ketoconazole is an effective and a relatively safe alternative in the treatment of hirsutism. Aust N Z J Obstet Gynaecol. 36:1996;487-489.
18. Gal M., Edlar-Geva T., Margalioth E.J., Barr I., Oryl J., Diamanti Z. Attenuation of ovarian response by low-dose ketoconazole during superovulation in patients with polycystic ovary syndrome. Fertil Steril. 27:1999;26-31.
19. Insler V., Lunenfeld E., Lunenfeld B. Ovarian hyperstimulation syndrome. Rabe T., Diedrich K., Runnebaum B. Manual on assisted reproduction. 1997;154-169 Springer, Berlin.
20. Lunenfeld B., Insler V., Rabau E. Induction de l'ovulation par les gonadotrophines. Oricard R., Ferrin J. L'ovulation. 1969;27 Masson, Paris.
21. Gal M., Orly J., Barr I., Algur N., Boldes R., Diamant Y.Z. Low dose ketoconazole attenuates serum androgen levels in patients with polycystic ovary syndrome and inhibits ovarian steroidogenesis in vitro. Fertil Steril. 61:1994;823-832.
22. Zelinski-Wooten M.B., Hess D.L., Wolf D.P., Stouffer R.L. Steroid reduction during ovarian stimulation impairs oocyte fertilization, but not folliculogenesis, in rhesus monkeys. Fertil Steril. 61:1994;1147-1155.
23. Moudgal N.R., Shetty G., Selvaraj N., Bhatnagar A.S. Use of a specific inhibitor for determining whether there is a role for estrogen in follicle/oocyte maturation, ovulation and preimplantation embryo development. J Reprod Fertil Suppl. 50:1996;69-81.